These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32369835)

  • 1. Is Exercise-Induced Fatigue a Problem in Children with Duchenne Muscular Dystrophy?
    Blaschek A; Rodrigues M; Ille L; Idriess M; Well T; Warken B; Müller C; Hannibal I; Tacke M; Müller-Felber W; Vill K
    Neuropediatrics; 2020 Oct; 51(5):342-348. PubMed ID: 32369835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Elfring GL; Atkinson L; Reha A; Hirawat S; Miller LL
    Muscle Nerve; 2010 Apr; 41(4):500-10. PubMed ID: 19941337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The assisted 6-minute cycling test to assess endurance in children with a neuromuscular disorder.
    Jansen M; De Jong M; Coes HM; Eggermont F; Van Alfen N; De Groot IJ
    Muscle Nerve; 2012 Oct; 46(4):520-30. PubMed ID: 22987692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing electrical impedance myography measurements by using a multifrequency ratio: a study in Duchenne muscular dystrophy.
    Schwartz S; Geisbush TR; Mijailovic A; Pasternak A; Darras BT; Rutkove SB
    Clin Neurophysiol; 2015 Jan; 126(1):202-8. PubMed ID: 24929900
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W
    Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48 weeks from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence JM; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz S
    Muscle Nerve; 2013 Sep; 48(3):343-56. PubMed ID: 23681930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reliability of the walking energy cost test and the six-minute walk test in boys with Duchenne muscular dystrophy.
    Kempen JC; Harlaar J; van der Kooi AJ; de Groot IJ; van den Bergen JC; Niks EH; Verschuuren JJ; Brehm MA
    Neuromuscul Disord; 2014 Mar; 24(3):216-21. PubMed ID: 24365209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy.
    Montes J; McDermott MP; Martens WB; Dunaway S; Glanzman AM; Riley S; Quigley J; Montgomery MJ; Sproule D; Tawil R; Chung WK; Darras BT; De Vivo DC; Kaufmann P; Finkel RS;
    Neurology; 2010 Mar; 74(10):833-8. PubMed ID: 20211907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The 6-minute walk test and other clinical endpoints in duchenne muscular dystrophy: reliability, concurrent validity, and minimal clinically important differences from a multicenter study.
    McDonald CM; Henricson EK; Abresch RT; Florence J; Eagle M; Gappmaier E; Glanzman AM; ; Spiegel R; Barth J; Elfring G; Reha A; Peltz SW
    Muscle Nerve; 2013 Sep; 48(3):357-68. PubMed ID: 23674289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy.
    Mercuri E; Signorovitch JE; Swallow E; Song J; Ward SJ; ;
    Neuromuscul Disord; 2016 Sep; 26(9):576-83. PubMed ID: 27423700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lower Extremity Functional Outcome Measures in Duchenne Muscular Dystrophy-A Delphi Survey.
    Senesac CR; Lott DJ; Willcocks RJ; Duong T; Smith BK
    J Neuromuscul Dis; 2019; 6(1):75-83. PubMed ID: 30562905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a wearable device to assess sleep and motor function in Duchenne muscular dystrophy.
    Siegel BI; Cakmak A; Reinertsen E; Benoit M; Figueroa J; Clifford GD; Phan HC
    Muscle Nerve; 2020 Feb; 61(2):198-204. PubMed ID: 31725915
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy.
    Goemans N; Vanden Hauwe M; Signorovitch J; Swallow E; Song J;
    PLoS One; 2016; 11(10):e0164684. PubMed ID: 27737016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. North Star Ambulatory Assessment, 6-minute walk test and timed items in ambulant boys with Duchenne muscular dystrophy.
    Mazzone E; Martinelli D; Berardinelli A; Messina S; D'Amico A; Vasco G; Main M; Doglio L; Politano L; Cavallaro F; Frosini S; Bello L; Carlesi A; Bonetti AM; Zucchini E; De Sanctis R; Scutifero M; Bianco F; Rossi F; Motta MC; Sacco A; Donati MA; Mongini T; Pini A; Battini R; Pegoraro E; Pane M; Pasquini E; Bruno C; Vita G; de Waure C; Bertini E; Mercuri E
    Neuromuscul Disord; 2010 Nov; 20(11):712-6. PubMed ID: 20634072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ambulatory capacity and disease progression as measured by the 6-minute-walk-distance in Duchenne muscular dystrophy subjects on daily corticosteroids.
    Goemans N; van den Hauwe M; Wilson R; van Impe A; Klingels K; Buyse G
    Neuromuscul Disord; 2013 Aug; 23(8):618-23. PubMed ID: 23770101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.
    Arora H; Willcocks RJ; Lott DJ; Harrington AT; Senesac CR; Zilke KL; Daniels MJ; Xu D; Tennekoon GI; Finanger EL; Russman BS; Finkel RS; Triplett WT; Byrne BJ; Walter GA; Sweeney HL; Vandenborne K
    Muscle Nerve; 2018 Nov; 58(5):631-638. PubMed ID: 29742798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How do physical capacity, fatigue and performance differ in children with duchenne muscular dystrophy compared with their healthy peers?
    Mutlu A; Alkan H; Fırat T; Karaduman AA; Yilmaz OT
    Neurosciences (Riyadh); 2018 Jan; 23(1):39-45. PubMed ID: 29455220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steroid treatment and the development of scoliosis in males with duchenne muscular dystrophy.
    Alman BA; Raza SN; Biggar WD
    J Bone Joint Surg Am; 2004 Mar; 86(3):519-24. PubMed ID: 14996877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.